Short answer
Prime Medicine, Inc. (PRME) filed an 8-K current report with the SEC on March 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Full-year 2025 financial results released March 3, 2026: details in Exhibit 99.1 press release.
Prime Medicine, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Full-year 2025 financial results released March 3, 2026: details in Exhibit 99.1 press release
- PRME is a clinical-stage gene editing company; earnings releases signal cash runway and pipeline progress, key investor metrics
Item 7.01 · Regulation FD Disclosure
- Corporate presentation updated March 3, 2026, posted to investor relations website
- Full presentation available as Exhibit 99.2 in this 8-K filing for detailed strategic/pipeline updates
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Prime Medicine, Inc. 8-K filings
Get the next PRME 8-K as it lands
Follow PRME for push alerts, or ask the research agent what this filing means.